Cardio-Renal-
Studies
Introduction
Cardiovascular and renal pathways are deeply interconnected. Many innovative therapies now target this full continuum rather than a single organ system.
At DELPHINIUM, we offer early-phase clinical studies with a dedicated cardiorenal focus, combining our in-house Phase I unit with a strong academic network. We also enable smooth transitions from first-in-human to proof-of-concept, including combined designs with a healthy volunteer part (SAD) and a patient part (MAD) within one protocol.
The cardiorenal cluster refers to tightly linked conditions such as heartfailure, chronic kidney disease and hypertension, often in association with metabolic disorders like type 2 diabetes, obesity, atherosclerotic disease and dyslipidemia. These conditions share common biological pathways, frequently occur together, and amplify each other’s risks.
An integrated Phase I cardiorenal platform
We support sponsors from early concept through full clinical execution, with a focus on cardiorenal relevant endpoints:
- Assistance with feasibility and endpoint selection
- Protocol input on renal, cardiovascular and metabolic measurements
- Integration of specialized cardio-renal-metabolic techniques into Phase I designs
- Operational execution in our clinic, including volunteer and patient recruitment
Our aim is to provide early, high-resolution insight into how your compound affects cardiovascular and renal pathways, and to de-risk the transition into Phase II with robust safety, PK/PD and early efficacy signals.
Strategic academic partnerships
To extend our methodological depth, we collaborate closely with:
Prof. Van der Meer (UMCG)– extensive cardiovascular research expertise in heart failure and other cardiovascular disease
Prof. Ron Gansevoort (UMCG) – deep nephrology expertise and validated techniques for measured GFR and renal hemodynamics
Prof. Ross Arena – international expert in metabolic and exercise physiology, enabling robust assessment of functional and metabolic endpoints.
